LNTH
Lantheus Holdings, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$100.97
−0.01%Sep 5, 2026, 05:46 UTC
Lantheus Alpha Therapy, LLC, a director and 10% owner of Perspective Therapeutics, sold 42,129 shares of common stock for $131,219 on September 2, 2026.
Source:Aug 29, 2026, 11:41 UTC
Halper Sadeh LLC announced it is investigating the sale of Lantheus Holdings, Inc. to Curium US Holdings LLC for $102.50 per share in cash plus contingent value rights of up to $12.00 per share.
Source:Aug 14, 2026, 12:00 UTC
The U.S. Food and Drug Administration approved Lantheus Holdings' TAUKLARIFY (florquinitau F 18 injection), an F18-labeled tau PET imaging agent for evaluating Alzheimer's disease in adults with cognitive impairment.
Source:Aug 6, 2026, 11:00 UTC
Lantheus Holdings reported its financial results for the second quarter of 2026, with worldwide revenue of $388.2 million, GAAP fully diluted earnings per share of $1.11, and adjusted fully diluted earnings per share of $1.55.
Source:Aug 4, 2026, 08:50 UTC
HuaRun Shuanghe signed a repurchase agreement with Lantheus on June 16, 2026, under which Lantheus repurchased all rights to DEFINITY in China for $30 million, with payment in three installments; as of the announcement date, the first installment of $15 million had been received.
Source:Jul 27, 2026, 21:37 UTC
Curium is in talks to acquire Lantheus Holdings for about $7 billion.
Jun 29, 2026, 13:51 UTC
The U.S. Food and Drug Administration issued a Complete Response Letter to Lantheus Holdings Inc. regarding its New Drug Application for LNTH-2501, a PET diagnostic imaging kit for neuroendocrine tumors.
Source:Jun 26, 2026, 20:01 UTC
The FDA issued a Complete Response Letter to Lantheus regarding its New Drug Application for LNTH-2501 (Ga 68 edotreotide).
Source: